Molecular Partners Presents Positive Preclinical Data on Radio-DARPin and Switch-DARPin Programs at AACR 2025
AinvestFriday, Apr 25, 2025 4:02 pm ET
1min readMolecular Partners presents new preclinical data at AACR 2025, including positive IND-enabling data on MP0712, a DLL3-targeting Radio-DARPin, and initial preclinical data on a mesothelin-targeting Radio-DARPin. The company also presents additional preclinical proof-of-concept data on a logic-gated CD3 Switch-DARPin T cell engager with CD2 co-stimulation.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet